Generated by AI
Krystal Biotech, Inc. is a commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing genetic medicines for serious and rare diseases. Its lead product, VYJUVEK, is a redosable gene therapy approved for dystrophic epidermolysis bullosa, a rare inherited skin disorder. The company’s work centers on its proprietary HSV-1-based delivery platform, which supports programs across dermatology, respiratory, ophthalmology, oncology, and aesthetics. Through this platform, Krystal Biotech develops therapies designed to address high unmet medical needs and expand treatment options in specialized disease areas. Headquartered in Pittsburgh, Pennsylvania, Krystal Biotech plays a notable role in the gene therapy market by combining commercial operations with a broader pipeline of investigational genetic medicine candidates.
Website2100 Wharton Street
Pittsburgh, PA, 15203
United States
The latest articles about KRYS.
Abeona Therapeutics is rated a Hold, as Zevaskyn uptake and manufacturing remain uncertain, and its $135 million cash position could run out before 2028.
Krystal Biotech reported Q3 2026 net income of US$63.07 million with diluted EPS of US$2.05, beat consensus on earnings and revenue, and paired this with a new US$400 million share repurchase authorization that has no expiration date. The business leaned on continued VYJUVEK demand, including a 30% year over year revenue lift and progress on European pricing, while early KB113 data in Gorlin syndrome added pipeline depth alongside some timing shifts for other programs. We will now look at...
Summary of Nov 2's posts. Generated by AI.
Summary of Feb 26's posts. Generated by AI.
Summary of Nov 29's posts. Generated by AI.
Summary of Nov 2's posts. Generated by AI.
Investors talking about KRYS also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.